Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Published: 2026-04-20 11:43:04 ET SILO

Published on 04/20/2026 at 11:43 am EDT

Silo Pharma, Inc. highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders. Silo Pharma?s lead program, SPC-15, is an intranasal prophylactic treatment targeting PTSD, designed to leverage rapid nose-to-brain delivery for enhanced therapeutic effect and patient compliance. The program is being advanced under a 505(b)(2) regulatory pathway, potentially enabling a streamlined development timeline.

Key Highlights of SPC-15 (PTSD Program): Designed as a novel serotonin 4 (5-HT4) receptor agonist. Targeting prophylactic treatment of PTSD and stress-induced disorders. Administered via an intranasal formulation designed for rapid CNS delivery.

Backed by intellectual property licensed from Columbia University. Preparing for IND engagement with the FDA. Advanced drug delivery strategy.

Partnership for optimized intranasal device development. Focus on nose-to-brain delivery platforms, a rapidly emerging segment in CNS therapeutics.